Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01367535
Recruitment Status : Completed
First Posted : June 7, 2011
Last Update Posted : July 19, 2011
Information provided by:
Valeant Pharmaceuticals International, Inc.

Brief Summary:
This study is a single-center, randomized, open-label, active and placebo-controlled, parallel-group, conducted in healthy male volunteers who have been shown to be extensive metabolizers of dextromethorphan.

Condition or disease Intervention/treatment Phase
Healthy Adults Drug: SC Methylnaltrexone (MNTX) Drug: IV Methylnaltrexone (MNTX) Drug: Oral Paroxetine Drug: SC Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan
Study Start Date : March 2006
Actual Primary Completion Date : August 2006
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: SC Methylnaltrexone (MNTX)
Experimental: Arm 2 Drug: IV Methylnaltrexone (MNTX)
Active Comparator: Arm 3 Drug: Oral Paroxetine
Placebo Comparator: Arm 4 Drug: SC Placebo

Primary Outcome Measures :
  1. Plasma Concentration of MNTX [ Time Frame: 4 months ]
    The objective of this study is to assess the effect of SC or IV doses of MNTX on CYP450 2D6 activity.

Secondary Outcome Measures :
  1. Plasma Concentration of Paroxetine [ Time Frame: 4 months ]
    The objective of this study is to assess the effect of SC or IV doses of MNTX on CYP450 2D6 activity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy males between the ages of 18 and 55
  2. Non-Smokers
  3. Body weight range form 154-220 lbs
  4. No history of clinically significant metabolic disorders.

Exclusion Criteria:

  1. Any history of low CYP450 2D6 activity
  2. History of alcohol abuse or recreational drugs
  3. History of any clinically significant disease or condition affecting a major organ system
  4. Donation or loss of blood, 60 days proceeding to screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01367535

United States, New York
Progenics Pharmaceuticals
Tarrytown, New York, United States, 10591
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Study Director: Tage Ramakrishna, MD Progenics Pharmaceuticals, Inc.

Responsible Party: Tage Ramakrishna, M.D.;, Progenics Pharmaceuticals, Inc. Identifier: NCT01367535     History of Changes
Other Study ID Numbers: MNTX 1108
First Posted: June 7, 2011    Key Record Dates
Last Update Posted: July 19, 2011
Last Verified: July 2011

Additional relevant MeSH terms:
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Narcotic Antagonists
Sensory System Agents
Peripheral Nervous System Agents